dwyer-potentialfornovel-2020.pdf (493.89 kB)
Potential for novel biomarkers in diabetes-associated chronic kidney disease: Epigenome, metabolome, and gut microbiome
journal contribution
posted on 2020-01-01, 00:00 authored by Ashani Lecamwasam, E I Ekinci, R Saffery, Karen DwyerKaren DwyerDiabetes-associated chronic kidney disease is a pandemic issue. Despite the global increase in the number of individuals with this chronic condition together with increasing morbidity and mortality, there are currently only limited therapeutic options to slow disease progression. One of the reasons for this is that the current-day “gold standard” biomarkers lack adequate sensitivity and specificity to detect early diabetic chronic kidney disease (CKD). This review focuses on the rapidly evolving areas of epigenetics, metabolomics, and the gut microbiome as potential sources of novel biomarkers in diabetes-associated CKD and discusses their relevance to clinical practice. However, it also highlights the problems associated with many studies within these three areas—namely, the lack of adequately powered longitudinal studies, and the lack of reproducibility of results which impede biomarker development and clinical validation in this complex and susceptible population.
History
Journal
BiomedicinesVolume
8Issue
9Article number
341Pagination
1 - 14Publisher
MDPILocation
Basel, SwitzerlandPublisher DOI
Link to full text
ISSN
2227-9059eISSN
2227-9059Language
EnglishPublication classification
C1 Refereed article in a scholarly journalUsage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicineMedicine, Research & ExperimentalPharmacology & PharmacyResearch & Experimental Medicinediabeteschronic kidney diseasebiomarkerepigeneticsmetabolomicsgut microbiomeDNA METHYLATIONWIDE ASSOCIATIONREVEALSBLOODQUANTIFICATIONEPIDEMIOLOGYNEPHROPATHYPROGRESSIONSTAGEBiochemistry & Molecular Biology
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC